
Genmab A/S: stock overview
Price
$50.60
November 20, 2026Market cap $32.5B
What Ploutos Investor adds for Genmab A/S
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Genmab A/S had revenue of $3.7B in the fiscal year to December 31, 2025 and net income of $963M, a net margin of 25.9%. Revenue grew by 24.8% a year on average over the last 2 years. At $50.60 the shares trade at a P/E of 33.8, against a median of 4.8 over the last 3 fiscal years. It has net debt of $3.4B. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $32.5B
- 642M shares
- P/E
- 33.8
- Today33.8Median4.8
- Revenue, fiscal year
- $3.7B
- +24.8% a year over 2 years
- Net margin
- 25.9%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+24.8% a year over 2 years
Fiscal years in figures
GMAB's revenue, profit, cash flow and dividend with each year-end price, from 2017 to 2019, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $19.8B
- $32.5B
- Enterprise value
- $35.9B
- P/E 3-year median: 4.8
- 33.8
- EV / EBIT
- 33.8
- EV / Revenue
- 9.7
- P/B 3-year median: 3.4
- 5.6
- FCF yield 3-year median: 5.8%
- 3.5%
- Earnings yield 3-year median: 20.7%
- 3.0%
Profitability
- Gross margin
- 93.6%
- Operating margin
- 28.6%
- Net margin 3-year median: 27.0%
- 25.9%
- ROIC
- 7.8%
- ROIC, 5-year average
- 12.9%
- ROE, fiscal year
- 16.5%
Growth
- Revenue, yearly change
- +19.2%
- EPS, yearly change
- -87.3%
- FCF, yearly change
- +9.3%
- Revenue, average a year
- +24.8%
- EPS, average a year
- -51.7%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $1.7B
- Total debt
- $5.2B
- Net debt
- $3.4B
- Net debt / EBITDA
- –
- Interest cover
- 4.0x
- Current ratio
- –
Balance sheet of December 31, 2025.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- 1.32%
- Total returned
- 1.32%
- Shares, yearly change
- -2.9%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- GENMAB A/S
- CIK
- 1434265
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 642M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with GMAB
- JNJJohnson & Johnson+0,00%Compare with GMAB
- ABBVAbbVie+0,00%Compare with GMAB
- UNHUnitedHealth+0,00%Compare with GMAB
- MRKMerck & Company+0,00%Compare with GMAB
- AMGNAmgen+0,00%Compare with GMAB
- TMOThermo Fisher Scientific+0,00%Compare with GMAB
- ABTAbbott Laboratories+0,00%Compare with GMAB
The full analysis
What do Genmab A/S's filings show?
These are Genmab A/S's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is GMAB's market cap?
Genmab A/S's market cap is $32.5B, at a price of $50.60 on November 20, 2026 and 642M shares.
What is GMAB's P/E?
GMAB's P/E is 33.8, on earnings per share of $1.54 in the fiscal year to December 31, 2025. The median over the last 3 fiscal years was 4.8.
How much revenue does GMAB have?
Genmab A/S had revenue of $3.7B in the fiscal year to December 31, 2025. Over the last 2 years it changed by +24.8% a year on average.
Does GMAB pay a dividend?
No. Genmab A/S paid no regular dividend over the last 12 months.
Where do the figures come from?
From Genmab A/S's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.